First Marketing Authorizations in Europe for IQYMUNE®, LFB’s 10% Liquid Intravenous Immunoglobulin
LFB SA announces the first two marketing authorizations for its 10% liquid intravenous immunoglobulin (IVIg) in Europe, namely in the United Kingdom and in Denmark. Thirteen more national marketing authorizations in Europe are expected in the coming months. Simultaneously to this ongoing European decentralized procedure, registrations are to take place in 33 countries in rest of the world, for launches staggered between 2016 and 2020.
Since 26 th August 2015, LFB’s “new generation” 10% liquid IVIg has been registered in the United Kingdom and in Denmark since 4 th September, in the Core SmPC indications. This immunoglobulin has a high-level of purity, relying namely on an innovative manufacturing process developed by LFB for its liquid immunoglobulins.
For rare immune system disorders. LFB’s 10% liquid IVIg IQYMUNE® will allow clinicians to treat rare immunity disorders, mostly hereditary, such as Primary Immunodeficiencies, Immunologic Thrombocytopenic Purpura, Guillain-Barré syndrome and Kawasaki disease, and acquired conditions such as Secondary Immunodeficiency. These diseases concern dozens of thousands of people in Europe, calling for chronic care most of the time.
Immunoglobulins being more and more prescribed in rare and severe dysimmunitary neuropathic affections, LFB conducts two Phase III clinical trials in Europe in order to register IQYMUNE® in the indications of MMN and CIDP1, two severe dysimmunitary neuropathic diseases.
Registration on the way in 15 European countries. LFB chose a decentralized procedure for European registration, with the German Paul Ehrlich Institute (PEI) as the referent authority for the procedure. Following the United Kingdom and Denmark, registration for IQYMUNE® is expected in the following European countries: Austria, Germany, Belgium, Spain, Finland, Greece, Hungary, Italy, Luxemburg, the Netherlands, the Czech Republic, Slovakia and Sweden.
LFB reinforces its positions in Immunology. “The registrations for IQYMUNE® in Europe and in 33 countries are to contribute to LFB group’s rapidly growing international activity, with LFB currently making a third of its turnover with international business” points out Christian Béchon, CEO of the LFB group. “Given the increasing global demand in immunoglobulins, the launch of our 10% liquid IVIg, to start in 2016, is of strategic importance” adds Mr. Béchon. The registration of IQYMUNE® in many European countries is also a major milestone for LFB’s research and development policy, particularly active in the field of Immunology. “With two current phases III on IQYMUNE®, and the first anti-D monoclonal antibody under clinical trials (phase II b) in the world, for the prevention of hemolytic disease of the newborn, we have major developments to achieve in the coming years” stresses out Guillaume Bologna, General Manager Development for the LFB group.
IQYMUNE® is to represent as much as 9 tons capacity in 2025, thanks to additional manufacturing capacities with upcoming new fractionation plant in France (city of Arras) that is to start around 2020.
1 MMN: Multifocal Motor Neuropathy; CIDP: Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
About the LFB group
LFB group (
is a biopharmaceutical company that develops, manufactures, and markets
medicinal products for the treatment of serious and often rare diseases
in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care.
The LFB group is the leading manufacturer of plasma-derived medicinal
products in France and 6th worldwide, and is also among the leading
European companies for the development of new-generation medicinal
products or treatments based on biotechnologies.
The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group markets its products in more than 40 countries around the world with a global turnover of € 501, 9 million in 2014. www.lfb.fr
Follow the LFB group on the social networks
Sandrine Charrières – Executive VP Corporate Communications
Phone: +33 (1) 69 82 72 80
Phone: +33 (6) 15 51 49 40
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom